Home LiteratureArticle Details
PMID: 15039757 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review

Identifying epitopes of HIV-1 that induce protective antibodies.

Nature reviews. Immunology ·Vol. 4 ·No. 3 ·2004-03-00 ·Pages 199-210

Zolla-Pazner S

Abstract

暂无摘要

MeSH Terms
AIDS Vaccines/immunology CD4 Antigens/immunology Epitopes/immunology HIV Antibodies/immunology HIV Envelope Protein gp120/immunology HIV Envelope Protein gp41/immunology HIV-1/immunology Humans
Chemicals
AIDS Vaccines CD4 Antigens Epitopes HIV Antibodies HIV Envelope Protein gp120 HIV Envelope Protein gp41
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Zolla-Pazner Susan
New York Veterans Affairs Medical Center and NYU School of Medicine, New York 10016, USA. zollas01@endeavor.med.nyu.edu
References (131)
131 references, click to expand
  1. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    J Virol. 2001 May;75(9):4165-75 PMID: 11287566
  2. Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts.
    AIDS. 1988;2 Suppl 1:S41-5 PMID: 2465771
  3. New hope for an AIDS vaccine.
    Nat Rev Immunol. 2002 Apr;2(4):239-50 PMID: 12001995
  4. AIDS vaccines: back to 'plan A'.
    Nature. 2003 Jun 26;423(6943):912-4 PMID: 12827164
  5. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.
    AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1319-28 PMID: 8891111
  6. Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay.
    AIDS Res Hum Retroviruses. 2004 Apr;20(4):435-41 PMID: 15157362
  7. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.
    J Virol. 1990 Jun;64(6):2833-40 PMID: 1692349
  8. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.
    J Virol. 1988 Dec;62(12):4703-11 PMID: 2460639
  9. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  10. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  11. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.
    J Virol. 2003 Mar;77(6):3832-7 PMID: 12610158
  12. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Science. 2003 Jun 27;300(5628):2065-71 PMID: 12829775
  13. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.
    Virology. 2000 Mar 30;269(1):47-53 PMID: 10725197
  14. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
    J Infect Dis. 1995 May;171(5):1203-9 PMID: 7751695
  15. Diversity considerations in HIV-1 vaccine selection.
    Science. 2002 Jun 28;296(5577):2354-60 PMID: 12089434
  16. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
    J Biol Chem. 1990 Jun 25;265(18):10373-82 PMID: 2355006
  17. Neutralization of animal viruses.
    Curr Top Microbiol Immunol. 1993;183:1-149 PMID: 8354080
  18. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.
    Proc Natl Acad Sci U S A. 1987 Apr;84(8):2479-83 PMID: 2436231
  19. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Virology. 1994 Nov 1;204(2):609-15 PMID: 7941328
  20. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    AIDS Res Hum Retroviruses. 1993 Oct;9(10):985-96 PMID: 7506556
  21. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
    J Virol. 2000 Jan;74(1):254-63 PMID: 10590113
  22. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    J Virol. 2004 Mar;78(5):2394-404 PMID: 14963135
  23. Multivariate analysis of human immunodeficiency virus type 1 neutralization data.
    J Virol. 1996 Sep;70(9):6235-43 PMID: 8709250
  24. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.
    Immunol Lett. 1996 Jun;51(1-2):107-14 PMID: 8811353
  25. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
    J Infect Dis. 2004 Jan 1;189(1):71-4 PMID: 14702155
  26. Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions.
    J Biol Chem. 1997 Aug 15;272(33):20420-6 PMID: 9252350
  27. Contrasting IgG structures reveal extreme asymmetry and flexibility.
    J Mol Biol. 2002 May 24;319(1):9-18 PMID: 12051932
  28. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
    Int Immunol. 1997 Sep;9(9):1281-90 PMID: 9310831
  29. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.
    J Immunol. 1990 Nov 15;145(10):3276-82 PMID: 1700004
  30. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
    J Virol. 2000 Feb;74(4):1961-72 PMID: 10644369
  31. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
    J Virol. 1996 Nov;70(11):7827-32 PMID: 8892904
  32. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    J Virol. 2003 Mar;77(5):2859-65 PMID: 12584309
  33. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    J Virol. 2002 Sep;76(18):9035-45 PMID: 12186887
  34. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.
    J Virol. 2003 Oct;77(19):10557-65 PMID: 12970440
  35. Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1.
    AIDS. 1991 Nov;5(11):1309-14 PMID: 1722676
  36. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.
    J Virol. 1991 Sep;65(9):4832-8 PMID: 1714520
  37. Antibodies, viruses and vaccines.
    Nat Rev Immunol. 2002 Sep;2(9):706-13 PMID: 12209139
  38. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3238-42 PMID: 2014246
  39. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8 PMID: 11997472
  40. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
    Vaccine. 2000 Dec 8;19(9-10):1068-81 PMID: 11137241
  41. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
    J Virol. 1998 Dec;72(12):9855-64 PMID: 9811721
  42. Importance of basic residues and quaternary structure in the function of MIP-1 beta: CCR5 binding and cell surface sugar interactions.
    Biochemistry. 2001 Apr 24;40(16):4990-9 PMID: 11305915
  43. A general model for the transmembrane proteins of HIV and other retroviruses.
    AIDS Res Hum Retroviruses. 1989 Aug;5(4):431-40 PMID: 2788443
  44. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization.
    J Exp Med. 1997 Oct 20;186(8):1287-98 PMID: 9334368
  45. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
    J Virol. 1998 Jun;72(6):4694-703 PMID: 9573233
  46. Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.
    J Virol. 1999 May;73(5):4042-51 PMID: 10196300
  47. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
    J Virol. 1995 Jan;69(1):122-30 PMID: 7527082
  48. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
    J Virol. 2003 Feb;77(4):2310-20 PMID: 12551968
  49. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.
    J Virol. 2000 Jul;74(13):6186-92 PMID: 10846104
  50. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    J Virol. 2001 Nov;75(22):10892-905 PMID: 11602729
  51. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.
    J Virol. 1994 Jun;68(6):4031-4 PMID: 7514684
  52. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.
    AIDS. 1995 Aug;9(8):867-74 PMID: 7576320
  53. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    J Virol. 2002 Jul;76(14):7306-21 PMID: 12072529
  54. Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides.
    Virology. 2000 May 25;271(1):182-96 PMID: 10814583
  55. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.
    J Virol. 1995 Jun;69(6):3807-15 PMID: 7745728
  56. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
    J Virol. 1994 Nov;68(11):6994-7000 PMID: 7933081
  57. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  58. Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response.
    Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7783-7 PMID: 1909030
  59. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  60. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    J Infect Dis. 1996 Feb;173(2):340-8 PMID: 8568294
  61. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  62. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
    J Virol. 1996 Jan;70(1):427-44 PMID: 8523556
  63. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
  64. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
    J Virol. 1998 Oct;72(10):7840-5 PMID: 9733820
  65. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.
    J Immunol. 1997 Nov 15;159(10):5114-22 PMID: 9366441
  66. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
    J Virol. 2002 Jul;76(13):6780-90 PMID: 12050391
  67. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):221-32 PMID: 8673526
  68. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.
    J Virol. 2001 Jul;75(14):6692-9 PMID: 11413337
  69. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    J Infect Dis. 1993 Jul;168(1):207-10 PMID: 8515110
  70. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.
    J Virol. 2001 Nov;75(22):10906-11 PMID: 11602730
  71. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.
    AIDS Res Hum Retroviruses. 1992 Jun;8(6):1099-106 PMID: 1380257
  72. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    J Virol. 2001 Jun;75(12):5526-40 PMID: 11356960
  73. HIV. Escape artist par excellence.
    Science. 2003 Mar 7;299(5612):1505-8 PMID: 12624245
  74. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    J Virol. 2000 Aug;74(15):7096-107 PMID: 10888650
  75. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  76. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    J Virol. 1995 Nov;69(11):6609-17 PMID: 7474069
  77. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications.
    Vaccine. 2001 Feb 28;19(15-16):1837-48 PMID: 11228353
  78. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.
    J Virol. 2003 Jan;77(1):353-65 PMID: 12477840
  79. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
    J Immunol. 2002 Jul 1;169(1):595-605 PMID: 12077293
  80. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    Science. 1996 May 10;272(5263):872-7 PMID: 8629022
  81. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.
    Structure. 2004 Feb;12(2):193-204 PMID: 14962380
  82. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
    J Immunol. 1993 Jan 15;150(2):635-43 PMID: 7678279
  83. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera.
    J Immunol. 1999 May 15;162(10):6155-61 PMID: 10229859
  84. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.
    J Virol. 2003 Feb;77(3):1666-71 PMID: 12525600
  85. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.
    Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43 PMID: 1384050
  86. HIV entry and its inhibition.
    Cell. 1998 May 29;93(5):681-4 PMID: 9630213
  87. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.
    AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):893-905 PMID: 10875615
  88. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
    AIDS Res Hum Retroviruses. 1997 May 1;13(7):575-82 PMID: 9135875
  89. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  90. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein.
    Vaccine. 2000 Nov 22;19(7-8):684-93 PMID: 11115689
  91. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    J Virol. 2002 Mar;76(5):2123-30 PMID: 11836389
  92. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma.
    Ann N Y Acad Sci. 2001 Sep;941:106-22 PMID: 11594564
  93. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity.
    Structure. 2003 Feb;11(2):225-36 PMID: 12575942
  94. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
    AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1207-17 PMID: 12487827
  95. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Science. 2001 Aug 10;293(5532):1155-9 PMID: 11498595
  96. Identification of a major co-receptor for primary isolates of HIV-1.
    Nature. 1996 Jun 20;381(6584):661-6 PMID: 8649511
  97. A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response.
    J Virol. 1995 Dec;69(12):7668-73 PMID: 7494275
  98. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Virology. 1995 Jan 10;206(1):713-7 PMID: 7530400
  99. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype.
    AIDS Res Hum Retroviruses. 1996 Jan 20;12(2):83-90 PMID: 8834457
  100. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  101. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  102. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    J Virol. 1994 Sep;68(9):6006-13 PMID: 8057475
  103. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
    Structure. 2000 Dec 15;8(12):1329-39 PMID: 11188697
  104. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
    Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597-601 PMID: 1700435
  105. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
    J Virol. 2002 Sep;76(17):8953-7 PMID: 12163614
  106. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
    J Virol. 2001 May;75(9):4258-67 PMID: 11287575
  107. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.
    Vaccine. 1998 Nov;16(19):1803-11 PMID: 9795384
  108. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
    Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):461-5 PMID: 1370580
  109. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Virology. 1997 Mar 17;229(2):360-9 PMID: 9126249
  110. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    J Virol. 2003 May;77(10):5889-901 PMID: 12719582
  111. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120.
    J Virol. 2001 Nov;75(22):10950-7 PMID: 11602735
  112. NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding.
    Structure. 2000 Apr 15;8(4):385-95 PMID: 10801487
  113. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.
    J Virol. 2000 May;74(10):4448-55 PMID: 10775580
  114. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  115. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
  116. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
    Nature. 1992 Feb 20;355(6362):728-30 PMID: 1741059
  117. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1737-48 PMID: 11788025
  118. Human immunodeficiency virus (HIV) type 1 antibodies in perinatal HIV-1 infection: association with human HIV-1 transmission, infection, and disease progression. For the Women and Infants Transmission Study.
    J Infect Dis. 2000 Oct;182(4):1243-6 PMID: 10979926
  119. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
    J Virol. 1992 Dec;66(12):7538-42 PMID: 1433529
  120. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
    J Immunol. 1994 Apr 15;152(8):4139-48 PMID: 8144976
  121. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.
    J Virol. 2003 May;77(10):5678-84 PMID: 12719560
  122. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    AIDS Res Hum Retroviruses. 1995 Nov;11(11):1379-91 PMID: 8573396
  123. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  124. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.
    Virology. 1993 Apr;193(2):709-16 PMID: 7681612
  125. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.
    AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):911-24 PMID: 8798976
  126. Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization.
    AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S247-54 PMID: 9814951
  127. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
    Science. 1986 Dec 12;234(4782):1392-5 PMID: 2431482
  128. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    J Gen Virol. 1996 Sep;77 ( Pt 9):2001-8 PMID: 8810996
  129. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum.
    J Infect Dis. 1995 Jun;171(6):1387-98 PMID: 7769272
  130. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    J Virol. 1993 Aug;67(8):4557-65 PMID: 8331723
  131. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Nat Med. 1999 Feb;5(2):204-10 PMID: 9930869
Article Info
Journal
Nature reviews. Immunology
Abbr.
Nat Rev Immunol
ISSN
1474-1733
DOI
10.1038/nri1307
Email
zollas01@endeavor.med.nyu.edu
Published
2004-03-00
Pages
199-210
Language
English
Region
England
NLM ID
101124169
PMCID
PMC7097025
Subset
IM
External Links
PubMed source DOI: 10.1038/nri1307 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2